Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYB002 Booster for COVID-19
NCT05928468Phase 1Unknown
- Sponsor
- Patronus Biotech
- Start
- Apr 2023
- Primary completion
- Jul 2023
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LYB002V14A in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Patronus Biotech. Primary endpoints: Frequencies and percentages of adverse events within 30 minutes of each booster dose, Frequencies and percentages of adverse events within 7 days of each booster dose and 4 more. Status: unknown.
02
Drugs
LYB002V14A
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05928468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05928468.